ATE296812T1 - 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms - Google Patents

1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms

Info

Publication number: ATE296812T1
Authority: AT; Austria
Prior art keywords: compounds; gamma; interleukin; diseases; inhibitors
Prior art date: 1998-03-09

Application number

AT99909935T

Other languages

English (en)

Inventor

Marion W Wannamaker

Paul Charifson

David J Lauffer

Michael D Mullican

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-09

Filing date

1999-03-09

Publication date

2005-06-15

1999-03-09 Application filed by Vertex Pharma filed Critical Vertex Pharma

2005-06-15 Application granted granted Critical

2005-06-15 Publication of ATE296812T1 publication Critical patent/ATE296812T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 3
108090000426 Caspase-1 Proteins 0.000 title abstract 2
QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical class C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
102100037850 Interferon gamma Human genes 0.000 abstract 4
108010074328 Interferon-gamma Proteins 0.000 abstract 4
108010076667 Caspases Proteins 0.000 abstract 3
102000011727 Caspases Human genes 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
102000000589 Interleukin-1 Human genes 0.000 abstract 2
108010002352 Interleukin-1 Proteins 0.000 abstract 2
102000003810 Interleukin-18 Human genes 0.000 abstract 2
108090000171 Interleukin-18 Proteins 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
229960003130 interferon gamma Drugs 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
208000035473 Communicable disease Diseases 0.000 abstract 1
-1 apoptosis- Proteins 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000001066 destructive effect Effects 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000001939 inductive effect Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Hematology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Obesity (AREA)
Psychiatry (AREA)

AT99909935T 1998-03-09 1999-03-09 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms ATE296812T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7732798P	1998-03-09	1998-03-09
PCT/US1999/005124 WO1999046248A1 (en)	1998-03-09	1999-03-09	1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors

Publications (1)

Publication Number	Publication Date
ATE296812T1 true ATE296812T1 (de)	2005-06-15

Family

ID=22137418

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99909935T ATE296812T1 (de)	1998-03-09	1999-03-09	1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms

Country Status (8)

Country	Link
US (1)	US6426413B1 (de)
EP (1)	EP1062210B1 (de)
JP (1)	JP4499917B2 (de)
AT (1)	ATE296812T1 (de)
AU (1)	AU2901899A (de)
DE (1)	DE69925581T2 (de)
ES (1)	ES2244178T3 (de)
WO (1)	WO1999046248A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050033033A1 (en) *	1998-05-04	2005-02-10	Heinz Kohler	Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) *	1998-05-04	2009-08-04	Innexus Biotechnology International Limited	Autophilic antibodies
US20040185039A1 (en) *	2002-08-30	2004-09-23	Heinz Kohler	Therapeutic applications of noncovalent dimerizing antibodies
US20090208418A1 (en) *	2005-04-29	2009-08-20	Innexus Biotechnology Internaltional Ltd.	Superantibody synthesis and use in detection, prevention and treatment of disease
AU5762899A (en) *	1999-09-17	2001-04-24	Lg Chemical Ltd.	Caspase inhibitor
US7253169B2 (en)	1999-11-12	2007-08-07	Gliamed, Inc.	Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) *	1999-11-12	2002-07-09	Gpi Nil Holdings, Inc.	AZA compounds, pharmaceutical compositions and methods of use
PT1390070T (pt) *	2001-05-25	2017-03-01	Ares Trading Sa	Utilização de inibidores de il-18 para o tratamento ou prevenção de lesões do snc
MY143582A (en)	2001-06-26	2011-05-31	Amgent Fremont Inc	Antibodies to opgl
UA78516C2 (en) *	2001-08-10	2007-04-10	Applied Research Systems	Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
HRP20050089B1 (hr) *	2002-07-29	2015-06-19	Rigel Pharmaceuticals	Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
ME00204B (me)	2002-09-06	2011-02-10	Medarex Llc	Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
AU2003275304A1 (en) *	2002-10-01	2004-04-23	Musc Oundation For Research Development	Use of caspase inhibitors as therapeutic agent against radiation-induced injury
GB0329572D0 (en) *	2003-12-20	2004-01-28	Astrazeneca Ab	Amide derivatives
MXPA06013256A (es) *	2004-05-15	2007-02-08	Vertex Pharma	Tratamiento de crisis convulsivas utilizando inhibidores ice.
JP2009502922A (ja)	2005-07-28	2009-01-29	バーテックスファーマシューティカルズインコーポレイテッド	カスパーゼ阻害剤プロドラッグ
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
ES2296484B1 (es) *	2005-11-23	2009-04-01	Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%)	Composicion farmaceutica para inhibir la apoptosis.
US12403181B2 (en)	2018-08-13	2025-09-02	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023225277A1 (en) *	2022-05-19	2023-11-23	Ohio State Innovation Foundation	Peptidyl flavor modifiers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874424A (en)	1995-12-20	1999-02-23	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en)	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
US4465679A (en)	1983-01-31	1984-08-14	Usv Pharmaceutical Corporation	1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en)	1983-08-12	1988-06-30	Takeda Chemical Industries Ltd	3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en)	1986-12-22	1991-10-08	Syntex Inc.	Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en)	1986-12-22	1992-10-27	Syntex (U.S.A.) Inc.	Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en)	1988-10-27	1991-04-16	University Of Kentucky Research Foundation	Novel peptidyl carbamate inhibitors of the enzyme elastase
CA2021660A1 (en)	1989-07-26	1991-01-27	Philippe Bey	Peptidase inhibitors
NZ235155A (en)	1989-09-11	1993-04-28	Merrell Dow Pharma	Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
US5416013A (en)	1990-04-04	1995-05-16	Sterling Winthrop Inc.	Interleukin 1β protease and interleukin 1β protease inhibitors
WO1991015577A1 (en)	1990-04-04	1991-10-17	Black, Roy, A.	INTERLEUKIN 1'beta' PROTEASE
EP0519748B1 (de)	1991-06-21	1998-09-02	Merck & Co. Inc.	Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
JP3190431B2 (ja)	1991-07-01	2001-07-23	三菱化学株式会社	ケトン誘導体
US5278061A (en)	1991-08-16	1994-01-11	Merck & Co., Inc.	Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
DE69229252T2 (de)	1991-08-16	1999-12-16	Merck & Co., Inc.	DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
EP0533226A3 (en)	1991-08-16	1993-08-18	Merck & Co. Inc.	Novel chromophore containing compounds
US6348570B1 (en)	1991-08-16	2002-02-19	Merck & Co., Inc.	Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP1378573A1 (de)	1991-08-30	2004-01-07	Vertex Pharmaceuticals Incorporated	Interleukin-1-beta-protease und Interleukin-1-beta-protease Inhibitoren
GB9123326D0 (en)	1991-11-04	1991-12-18	Sandoz Ltd	Improvements in or relating to organic compounds
EP0547699A1 (de)	1991-12-19	1993-06-23	Merck & Co. Inc.	Peptidylderivate als Inhibitoren von Interleukin-1-Beta-konvertierenden Enzymen
AU3479593A (en)	1992-01-31	1993-09-01	Merck & Co., Inc.	Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
DE69320176T2 (de)	1992-02-21	1999-04-08	Merck & Co., Inc., Rahway, N.J.	Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms
JPH08500242A (ja)	1992-06-24	1996-01-16	メルクエンドカンパニーインコーポレーテッド	インターロイキン１β前駆体の転換酵素をコードするＤＮＡ
JP2602181B2 (ja)	1992-07-31	1997-04-23	ファイザー・インク．	消炎薬としてのペプチジル４−アミノ−２，２−ジフルオロ−３−オクソ−１，６−ヘキサン二酸誘導体
CA2109646C (en)	1992-11-24	2000-03-07	Gaston O. Daumy	Para-nitroanilide peptides
EP0618223A3 (de)	1993-03-08	1996-06-12	Sandoz Ltd	Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
CA2122227A1 (en)	1993-04-29	1994-10-30	Roland E. Dolle	Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en)	1993-05-07	1995-10-31	Sterling Winthrop Inc.	Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en)	1993-05-17	1995-05-02	Merck & Co., Inc.	Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja)	1993-06-03	1995-04-04	Sterling Winthrop Inc	インターロイキン−１β転換酵素阻害剤
DK0644197T3 (da)	1993-06-04	1999-06-07	Vertex Pharma	Peptidphosphinyloxymethylketoner som inhibitorer af interleukin-1beta-konverterende enzymer
US5446128A (en) *	1993-06-18	1995-08-29	The Board Of Trustees Of The University Of Illinois	Alpha-helix mimetics and methods relating thereto
US6083735A (en)	1993-06-24	2000-07-04	The General Hospital Corporation	Programmed cell death genes and proteins
WO1995005192A1 (en)	1993-08-13	1995-02-23	Merck & Co., Inc.	SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5486623A (en)	1993-12-08	1996-01-23	Prototek, Inc.	Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en)	1993-12-08	1998-02-03	Prototek, Inc.	α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
ES2210289T3 (es)	1994-03-31	2004-07-01	Vertex Pharmaceuticals Incorporated	Derivados de pirimidinilo como inhibidores de interleuquinas.
CA2189036A1 (en)	1994-04-29	1995-11-09	Roland E. Dolle	Halomethyl amides as il-1.beta. protease inhibitors
US5492824A (en)	1994-05-12	1996-02-20	Basf Ag	Ice and ice-like compositions and methods of making same
US5552400A (en) *	1994-06-08	1996-09-03	Sterling Winthrop Inc.	Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5856116A (en)	1994-06-17	1999-01-05	Vertex Pharmaceuticals, Incorporated	Crystal structure and mutants of interleukin-1 beta converting enzyme
US5716929A (en) *	1994-06-17	1998-02-10	Vertex Pharmaceuticals, Inc.	Inhibitors of interleukin-1β converting enzyme
US5565430A (en)	1994-08-02	1996-10-15	Sterling Winthrop Inc.	Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5498616A (en)	1994-11-04	1996-03-12	Cephalon, Inc.	Cysteine protease and serine protease inhibitors
TW394764B (en)	1995-02-14	2000-06-21	Mitsubishi Chemcal Corp	Oxygen-containing heterocyclic derivatives
US6162828A (en)	1995-03-31	2000-12-19	Takeda Chemical Industries, Ltd.	Cysteine protease inhibitor
US5635504A (en) *	1995-06-07	1997-06-03	Bristol-Myers Squibb Co.	Diazepine containing dual action inhibitors
JPH11511463A (ja)	1995-08-31	1999-10-05	スミスクライン・ビーチャム・コーポレイション	インターロイキン変換酵素およびアポプトーシス
WO1997007805A1 (en)	1995-08-31	1997-03-06	Smithkline Beecham Corporation	Interleukin converting enzyme and apoptosis
US6136834A (en)	1995-12-27	2000-10-24	Ono Pharmaceutical Co., Ltd.	Tetrazole compounds and pharmaceutical agents containing such derivative
WO1998004539A1 (en)	1996-07-29	1998-02-05	Mitsubishi Chemical Corporation	Oxygenic heterocyclic derivatives
ATE229973T1 (de)	1996-09-12	2003-01-15	Idun Pharmaceuticals Inc	C-terminale modifizierte (n-substituierte)-2- indolyl dipeptide als inhibitoren von der ice/ced-3 cysteinprotease familie
ES2255112T3 (es)	1996-09-12	2006-06-16	Idun Pharmaceuticals, Inc.	Inhibicion de apoptosis usando inhibidores de la familia de la enzima convertidora de interleucina 1-beta (ice)/ced-3.
NZ330451A (de)	1996-09-12	2000-01-28	Idun Pharmaceuticals Inc
HUP9700816A3 (en)	1997-04-28	1999-06-28	Gyogyszerkutato Intezet	3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta

1999
- 1999-03-09 JP JP2000535629A patent/JP4499917B2/ja not_active Expired - Fee Related
- 1999-03-09 AT AT99909935T patent/ATE296812T1/de not_active IP Right Cessation
- 1999-03-09 WO PCT/US1999/005124 patent/WO1999046248A1/en not_active Ceased
- 1999-03-09 ES ES99909935T patent/ES2244178T3/es not_active Expired - Lifetime
- 1999-03-09 AU AU29018/99A patent/AU2901899A/en not_active Abandoned
- 1999-03-09 EP EP99909935A patent/EP1062210B1/de not_active Expired - Lifetime
- 1999-03-09 DE DE69925581T patent/DE69925581T2/de not_active Expired - Lifetime
2000
- 2000-09-05 US US09/654,855 patent/US6426413B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1062210B1 (de)	2005-06-01
DE69925581T2 (de)	2006-04-27
EP1062210A1 (de)	2000-12-27
AU2901899A (en)	1999-09-27
WO1999046248A1 (en)	1999-09-16
JP4499917B2 (ja)	2010-07-14
DE69925581D1 (de)	2005-07-07
HK1033828A1 (en)	2001-09-28
ES2244178T3 (es)	2005-12-01
US6426413B1 (en)	2002-07-30
JP2002506061A (ja)	2002-02-26

Legal Events

Date

Code

Title

Description

2006-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1062210

Country of ref document: EP

2010-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69736984D1 (de)	2007-01-04	Inhibitoren des interleukin-1-beta konvertierenden enzyms
BG104863A (en)	2001-04-30	Inhibitors of caspases
ATE296812T1 (de)	2005-06-15	1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
ATE290545T1 (de)	2005-03-15	Inhibitoren des interleukin-1beta konvertierenden enzyms
ATE310011T1 (de)	2005-12-15	Inhibitoren des interleukin-1-beta konvertierenden enzyms
EP2295442A3 (de)	2011-04-06	Inhibitoren von Interleukin-1beta Converting-Enzym
PT966465E (pt)	2003-11-28	Inibidores do enzima imfdh
BRPI0015533B8 (pt)	2021-05-25	enzima alfa-l-iduronidase humana recombinante, composição farmacêutica compreendendo a mesma e método para sua purificação
ID19142A (id)	1998-06-18	Inhibitor-inhibitor sikloalkil pada protein farnesiltransferase
BRPI9917881B8 (pt)	2021-05-25	compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos